Farallon Capital Shows DermTech Stake ~ market folly

Wednesday, September 11, 2019

Farallon Capital Shows DermTech Stake

Andrew Spokes' hedge fund firm Farallon Capital has filed a 13G with the SEC regarding shares of DermTech (DMTK).  Per the filing, Farallon now owns 9.8% of DermTech as of August 29th with exposure to over 1.23 million shares. 

Their stake is comprised of 615,385 shares and they also hold "Series A Preferred Shares (as defined in the Preliminary Note) convertible into an aggregate of 615,385 shares."

DermTech shares have been extremely volatile, plummeting from $21.69 in late August to around $5 by the end of the month.

Per Yahoo Finance, DermTech is "a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California."

blog comments powered by Disqus